More news articles

China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir

Raises concerns over patent exclusivity in the country

FDA sets Q3 decision date for NS Pharma’s DMD drug

If approved it will become second-to-market after Sarepta

Merck chases Roche with triple-negative breast cancer data for Keytruda

Data demonstrated a delay in disease progression or death

Revenue growth at Ipsen numbs pain of palovarotene calamity

French speciality drugmaker posted €2.58bn sales for the full-year

Janssen files new Darzalex combination for multiple myeloma

Expands use of anti-CD38 antibody even further

NICE turns down Keytruda/Inlyta combo for kidney cancer

Cost-effectiveness agency says the long-term benefit is uncertain

J&J gets US backing for vaccine against coronavirus, christened Covid-19

Death toll now stands at over 1,000 people

Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer

Hopes to extend the antibody drug conjugate's use into the earlier setting

Novartis plans inclisiran trial in the UK

Swiss pharma also officially opens new London headquarters

FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma

KTE-X19 is also under regulatory review with the EMA

Novartis pulls ahead of Merck in MET-positive lung cancer race

FDA starts priority review of Swiss pharma's MET inhibitor

Exelixis bounces back with new prostate cancer data

Announces encouraging results after initial trial fail

Botox strength bolsters Allergan ahead of AbbVie takeover

Speciality drugmaker posted a 6.6% sales increase in the last quarter

Four more coronavirus cases confirmed in the UK

Secretary of State declares outbreak a “serious and imminent threat”

Skyrizi, Rinvoq help AbbVie weather Humira slowdown

The company expects overall earnings growth to be around 8% this year

Double blow to amyloid drug hopes as Roche, Lilly trial fails

The two investigational candidates were unable to show benefit